StockData

Cartesian Therapeutics, Inc. (RNAC) stock

RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.12+0.04 (+0.66%)

Close on Nov 17, 2026Market cap $185.16MP/E –Yield –

Cartesian Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Cartesian Therapeutics's price to book ratio was 1.8× on Jan 31, 2024, against 3.2× a year earlier. Over the last 5 years it ranged from 1.8× to 41.1×, with a median of 4.4×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2024Jan 31, 20241.8×+0.1
2023Dec 29, 20231.8×−0.3
2022Dec 30, 20222.0×−25.7
2020Apr 30, 202027.8×+22.3
2019Jul 31, 20195.4×−2.6
2018Dec 31, 20188.0×+4.7
2017Dec 29, 20173.3×−1.4
2016Dec 30, 20164.8×–

More Cartesian Therapeutics figures

See a number that looks wrong?